The US Food and Drug Administration approvedFDAA new drug for type 2 diabetes helps improve glucose response in addition to diet and exercise.Medicalnewstoday“.
The site indicated that this drug is in the category of injectable double incretin agonists and is called tirzepatide It improves the glucose response in people with type 2 diabetes, and this drug is injected once a week, and the dose is determined according to the blood sugar level.
Clinical trials have proven that there are 3 different doses of tirzepatide Including 5 mg, 10 mg, and 15 mg, and the amount of injections is determined according to blood sugar, and it has been proven that these injections significantly reduce the cumulative rate of sugar in the body of the affected person, and also reduce blood sugar.
The report indicated that the injection is given to the patient as an injection once a week under the skin, and it has a double effect, as it lowers blood sugar and supports weight loss better than the currently available drugs for this condition.
The report provided some of the side effects of the injections, including nausea, diarrhea, and vomiting, which appear to reduce over time, and there have also been a few reports of severe low blood sugar in clinical trials..
